Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon Nov 23, 2023 9:06am
99 Views
Post# 35749791

RE:RE:RE:RE:Beedie conv. financing round 4!!!

RE:RE:RE:RE:Beedie conv. financing round 4!!!Looks like it'll be Monday morning. This may be the most anticipated and important earnings call in the companies history, and it's not for positive reasons. After this call we won't hear from the company again until the late April Q4 earnings call. Guidance on 2024 revenue, EBITDA, cash flow, and clear communication regarding anticipated needs for additional capital (i.e. shareholder dilution via convertible debt at cheap conversion prices) are sorely needed. Rhetoric about a pipeline that has yet to materialize are less helpful. Investors need to know when that pipeline will turn into revenue and EBITDA how big that opportunity is. So far all they've said is that it's big and coming but that narrative is starting to get old.
<< Previous
Bullboard Posts
Next >>